



Migraine: from bench to clinical practice

Dear Colleagues,

The management of patients with migraine is often unsatisfactory because available acute and preventive therapies are either ineffective or poorly tolerated. Chronic migraine is a very invalidating disease and research in the last year is growing up. Indeed, with the advent of new approaches, including botulin toxin, monoclonal antibodies and neuromodulation, clinicians have more weapons to fight this relevant problem. This special issue is aimed at investigating the importance of migraine as a common but still undertreated and overlooked problem. Papers dealing with the understanding of the pathogenetic mechanism subtending migraine,

as well as new treatments and patents, are particularly welcomed. They may include either animal models or clinical studies, with regard to prospective cohort studies or randomized clinical trials.

Ethical, legal and socio-relational concerns, including sexual dysfunction, are also of interest to the special issue.

Best regards,

Prof. Dr. Rocco Salvatore Calabrò

Keywords: Monoclonal antibodies; new molecules; migraine, neuromodulation

Deadline: 30 April 2022

Guest Editor(s):



Prof. Dr. Rocco Salvatore Calabrò

salbro77@tiscali.it

IRCCS Centro Neurolesi "Bonino Pulejo", Messina, Italy